Therapeutic targeting of the hepcidin-ferroportin axis and erythropoietic modulators: a narrative review
Ghaith K. Mansour, Ahmad W. Hajjar, Muhammad Raihan Sajid · 2025
Read Therapeutic targeting of the hepcidin-ferroportin axis and erythropoietic modulators: a narrative review by Ghaith K. Mansour, Ahmad W. Hajjar, Muhammad Raihan Sajid (2025) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-12722858.txt.
Description
Ghaith Mansour, Ahmad Hajjar, and Muhammad Sajid review treatments that target iron control in blood diseases. Iron balance hinges on hepcidin, a hormone that works through ferroportin, the only channel that exports iron from cells. When this axis fails, iron builds up or reaches the wrong tissues.
The review explains the signals that tune hepcidin, including bone morphogenetic protein pathways and erythroferrone. It surveys new drugs such as luspatercept, matriptase-2 blockers, and anti-hemojuvelin antibodies. It also covers ferroptosis, an iron-driven form of cell death now eyed as a drug target. Trial results show promise, though the authors stress gaps in patient selection and long-term proof.
Catalog record
| CREATOR | Ghaith K. Mansour, Ahmad W. Hajjar, Muhammad Raihan Sajid |
|---|---|
| YEAR | 2025 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 33 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |